Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-019-51137-5
DC FieldValue
dc.titleKawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children
dc.contributor.authorYung, C.F.
dc.contributor.authorMa, X.
dc.contributor.authorCheung, Y.B.
dc.contributor.authorOh, B.K.
dc.contributor.authorSoh, S.
dc.contributor.authorThoon, K.C.
dc.date.accessioned2021-12-29T04:05:47Z
dc.date.available2021-12-29T04:05:47Z
dc.date.issued2019
dc.identifier.citationYung, C.F., Ma, X., Cheung, Y.B., Oh, B.K., Soh, S., Thoon, K.C. (2019). Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children. Scientific Reports 9 (1) : 14705. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-019-51137-5
dc.identifier.issn20452322
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/212241
dc.description.abstractKawasaki disease (KD) is a systemic vasculitis mainly affecting young children and the leading cause of acquired heart disease in developed countries. We performed a self-controlled case series analysis to investigate the association between PCV13 and KD. All hospitalized KD cases <2 y old from our hospital in Singapore from 2010 to 2014 were included. Complete KD cases were classified based on the definitions of the American Heart Association. During the study period, 288 KD cases were identified. A total of 21 KD cases (12 were classified as Complete KD) had date of onset within the risk interval of day 1 to day 28 post PCV13. The age-adjusted Relative Incidence (RI) for KD following PCV13 dose 1, dose 2 and dose 3 were 1.40 (95%CI, 0.72 to 2.71), 1.23 (95% CI, 0.62 to 2.44) and 0.34 (95% CI, 0.08 to 1.40) respectively. There were seven Complete KD cases with onset during the risk interval after dose 1 of PCV13 (age-adjusted RI 2.59, 95%confidence interval (CI), 1.16 to 5.81). We did not detect a significant increased risk for overall KD among PCV13 recipients. However, a significant association between PCV13 and Complete KD was noted following receipt of the first dose of PCV13. © 2019, The Author(s).
dc.publisherNature Publishing Group
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2019
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/s41598-019-51137-5
dc.description.sourcetitleScientific Reports
dc.description.volume9
dc.description.issue1
dc.description.page14705
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-019-51137-5.pdf1.45 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons